CAPR

Business Context and Reporting Period

Company: Nile Therapeutics, Inc. (formerly SMI Products, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Nile is a development-stage biopharmaceutical company focused on cardiovascular diseases. It holds rights to two drug candidates: Cenderitide (lead candidate for heart failure, currently in Phase II) and CU-NP (pre-clinical). The company has no product revenue and relies on equity financing and grants to fund operations.

Key Financial Metrics

Note: The company reported no debt obligations as of December 31, 2010. Current liabilities totaled approximately $1.07 million, primarily accounts payable and accrued expenses.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $1.84 million (23%) compared to 2009, driven by reduced operating expenses.
• Expense Decreases:
  • G&A Expenses: Decreased by $1.21 million, primarily due to a $0.7 million reduction in stock-based compensation (accelerated vesting in 2009) and lower consulting/occupancy costs.
  • R&D Expenses: Decreased by $0.39 million, attributed to reduced manufacturing costs for Cenderitide and lower personnel expenses due to outsourcing, partially offset by increased clinical trial costs.
• Financing Activity: In April 2010, the company completed an underwritten public offering of 7.475 million units (stock + warrants), raising net proceeds of approximately $4.52 million. This contrasts with the July 2009 private placement which raised approximately $3.37 million.
• Grant Income: In Q4 2010, the company received a $244,479 grant under the Therapeutic Discovery Tax Credit program, recorded as "Other Income."

Guidance, Outlook, and Risks

Outlook and Guidance:

• Liquidity: Management believes current resources ($3.4 million cash) plus funding from a new Medtronic agreement are sufficient to fund operations beyond Q4 2011.
• Capital Needs: Substantial additional capital will be required to fund the next clinical study (Phase II) for Cenderitide, expected to initiate in 2012. The company anticipates needing financing by Q1 2012.
• Development Plan: Plans to initiate a Phase I PK/PD study for Cenderitide in Q2 2011 using subcutaneous micro-needle pump technology, funded by Medtronic.

Key Risks and Contingencies:

• Nasdaq Delisting: The company received notice of non-compliance with the $1.00 minimum bid price requirement. A hearing granted an extension until May 31, 2011, to regain compliance; failure to do so may result in delisting to the OTC Bulletin Board.
• Going Concern: The company has a history of net losses and negative cash flows. Continued operations depend on raising additional capital, which may not be available on acceptable terms.
• Regulatory & Clinical: Success depends on FDA approval of Cenderitide and CU-NP. Clinical trials are expensive and uncertain; failure to demonstrate efficacy or safety would halt commercialization.
• Intellectual Property: Rights to both drug candidates are licensed from the Mayo Foundation. Failure to meet milestone payments or maintain the license could result in loss of rights.

Investor Verification Checklist

• Cash Runway: Verify if the company has secured additional financing to bridge the gap beyond Q4 2011, as explicitly stated as a requirement for 2012 operations.
• Nasdaq Compliance: Monitor stock price performance to determine if the company will regain compliance with the $1.00 minimum bid price by the May 31, 2011 deadline.
• Medtronic Agreement: Confirm the execution and terms of the Clinical Trial Funding Agreement with Medtronic to ensure the Phase I study proceeds as planned.
• Related Party Transactions: Review the services agreement with Two River Consulting (controlled by directors/officers) and the associated monthly fees ($65,000) and stock option grants.
• Stock-Based Compensation: Assess the impact of future stock option grants and vesting schedules on future expense recognition and shareholder dilution.